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Because multiple myeloma (MM) remains incurable, new therapeutic approaches are needed. Proteasome inhibition represents a
new therapeutic strategy with the potential to inhibit multiple pathogenic pathways in MM. In phase I trials, the novel proteasome
inhibitor bortezomib demonstrated encouraging activity in patients with advanced MM. In the SUMMIT phase II trial, 202 heavily
pre-treated patients with relapsed and refractory MM received bortezomib 1.3 mg/m2 twice weekly for 2 weeks, followed by a
1-week rest. The overall response rate, deﬁned as complete + partial +minimal responses (CR+PR+MR), was 35%, with CR or
near-CR in 10% of patients. Median duration of response was 12 months and median duration of survival 16 months for all patients.
Adverse eﬀects included manageable gastrointestinal symptoms, thrombocytopaenia, and peripheral neuropathy. Thrombocyto-
paenia and neuropathy were generally reversible and occurred mainly in patients who already had these toxicities at time of en-
rollment. In the CREST phase II trial, 54 patients with relapsed or refractory MM after ﬁrst-line therapy were randomised to receive
bortezomib 1.0 mg or 1.3 mg/m2, twice weekly for 2 weeks, followed by a 1-week rest. Overall response rates were 33% at the 1.0 mg
dose and 50% at the 1.3 mg dose. Toxicities were similar to those seen in SUMMIT, with nausea, diarrhoea and peripheral neu-
ropathy occurring more frequently at the higher dose level. In conclusion, the results of the SUMMIT and CREST trials show that
bortezomib is highly active in patients with relapsed and refractory MM. A large phase III trial comparing bortezomib with
dexamethasone in relapsed MM patients was recently stopped after a pre-speciﬁed interim analysis showed a statistically signiﬁcant
improvement in time to disease progression for patients receiving bortezomib. Studies testing bortezomib as front-line therapy are
ongoing.
 2004 Elsevier Ltd. All rights reserved.
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Multiple myeloma (MM) is the second most common
haematological malignancy, with an estimated annual
incidence of approximately 75,000 cases worldwide [1].
Although most patients respond initially to treatment
with chemotherapy and radiation, the majority eventu-
ally relapse with chemo-resistant disease. Mechanisms
of resistance in MM involve both the myeloma cells
themselves and the protective interaction between my-
eloma cells and the bone marrow microenvironment [2].qResearch grants; clinical trial drug supply.
* Tel.: +33-2-40-08-32-50; fax: +33-2-40-08-32-71.
E-mail address: jlharousseau@sante.univ-nantes.fr (J.-L. Harous-
seau).
1359-6349/$ - see front matter  2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejcsup.2004.04.004Because MM remains incurable, new therapeutic ap-
proaches are needed.
The transcription factor nuclear factor-jB (NF-jB)
appears to play a central role in the pathogenesis of
myeloma. Tumor cells and bone marrow stromal cells
(BMSC) from patients with MM show enhanced NF-jB
activity compared with normal bone marrow, and
chemo-resistant MM cell lines show enhanced NF-jB
activity compared with sensitive lines [3,4]. Proteasome-
mediated activation of NF-jB results in the expression
of multiple cytokine and cell adhesion molecules pro-
moting myeloma cell growth and survival [5].
Inhibition of the proteasome thus represents a new
therapeutic strategy for MM, with the potential to in-
hibit multiple pathogenic pathways. In preclinical ex-
periments, the novel dipeptide boronic acid proteasome
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cells, but also downregulates protective interactions be-
tween MM cells and BMSC’s [6]. In addition, bortezo-
mib has been shown to markedly increase the sensitivity
of chemo-resistant MM cell lines to chemotherapeutic
agents such as melphalan and doxorubicin [3].
In a phase I trial in patients with refractory haema-
tologic malignancies, 27 patients were treated with doses
of bortezomib ranging from 0.40–1.38 mg/m2 by intra-
venous (IV) bolus twice weekly for 4 weeks, followed by
a 2-week rest. The study included 11 patients with MM
and one patient with Waldenstr€om’s macroglobulinae-
mia. Of the 12 patients with plasma cell dyscrasias, 9
completed at least one full cycle of therapy and were
assessable for response. A complete response by
Southwest Oncology Group (SWOG) criteria was doc-
umented in one patient with IgG-j myeloma treated at
the 1.04 mg/m2 dose level. The other eight patients with
myeloma experienced either a minor response or stable
disease [7].
Based on the strong preclinical rationale together
with these encouraging phase I clinical results, bort-
ezomib moved rapidly into phase II and III clinical
testing in patients with refractory and relapsed MM.
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Fig. 1. Previous myeloma therapy received by patients in the SUMMIT
trial [8,10].Mediannumber of lines of prior therapywas six (range 2–15).
Ninety-two percent of patients received at least three drug therapies
(excluding SCT) and 91% of patients were refractory to last therapy.
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Fig. 2. The SUMMIT trial: response rates. Of 193 evaluable patients,
therewas a 35%overall response rate (CR+PR+MR); 27%experienced
CR+PR; and 24% had stable disease (SD). Overall, 59% had SD or
better. Findings were assessed by Independent Review Committee [8].2. Bortezomib in patients with relapsed and refractory
myeloma: The SUMMIT trial
The SUMMIT trial was an open-label, multicenter,
phase II trial conducted in 202 patients [8]. Adult pa-
tients with MM in relapse after at least two prior lines of
treatment, and refractory to their last line of treatment,
were eligible. Other eligibility criteria included a Kar-
nofsky performance status (PS) of P 60, creatinine
clearance P 10 mL/min, haemoglobin P 8 g/dL,
platelet count P 30,000/mm3, and absolute neutrophil
count P 500/mm3. Patients were treated with bortezo-
mib 1.3 mg/m2 by IV bolus twice weekly for 2 weeks,
followed by 1 week rest, in 21-day cycles. Patients with
progressive disease after two cycles or stable disease
after four cycles were eligible to add treatment with
dexamethasone 20 mg p.o. on the day of and day after
each dose of bortezomib. Patients were permitted to
receive up to eight cycles of bortezomib; patients with
clinical beneﬁt could receive additional treatment in a
separate extension study. The primary study endpoint
was overall response rate, deﬁned as com-
plete + partial +minimal responses (CR+PR+MR) [8].
Responses were assessed by an independent review
committee according to the criteria of the European
Group for Blood and Marrow Transplantation (the
Blade criteria) [9]. Secondary endpoints were time to
progression, survival, safety, rate of response to bort-
ezomib in combination with dexamethasone, and qual-
ity of life. A complete response was deﬁned as normalserum calcium, stable skeletal disease, absence of soft-
tissue plasmacytomas, <5% plasma cells in the marrow
in two specimens obtained 6 weeks apart, and a negative
immunoﬁxation test for myeloma protein in serum and
urine. A near-complete response was deﬁned by the
absence of myeloma protein on electrophoresis, inde-
pendent of the immunoﬁxation-test result [8].
Most patients (84%) had IgG or IgA myeloma. At
baseline, 20% of patients had a Karnofsky PS of 6 70
and 80% had symptoms of peripheral neuropathy. Me-
dian time since diagnosis was 4 years, median serum
b2-microglobulin concentration was 3.5 mg/L, and 35%
of 172 patients tested had cytogenetic abnormalities,
including 15% with chromosome 13 deletion [8].
Fig. 1 shows the prior therapy received by patients
enrolled in the study. The median number of prior lines
of therapy was 6 [8,10]. Sixty-four percent had received
at least one autologous transplantation. Almost all pa-
tients had received corticosteroids, over 90% had been
treated with alkylating agents, and over 80% had
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Fig. 3. (a) The SUMMIT trial: duration of response (CR+PR+MR)
of patients receiving bortezomib alone over time [8]; N ¼ 67. (b)
Overall survival in the SUMMIT trial, shown over time [8,11]. As of
October 2002, the median overall survival was 16 months; with longer-
term follow-up, median survival has since been measured at 17.8
months.
14 J.-L. Harousseau / EJC Supplements Vol 2 No. 6 (2004) 12–17received thalidomide. Altogether, 92% of patients had
been treated with three or more of the major classes of
agents for myeloma. Ninety-one percent of patients were
refractory to their last prior line of therapy [8].
Fig. 2 shows the patient responses [8]. Overall, of 193
patients with measurable disease, 35% had a CR, PR, or
MR. Four percent of patients had a CR with negative
immunoﬁxation, and 6% of patients had a near-CR with
M-protein undetectable by electrophoresis, but with
immunoﬁxation remaining positive. In 12 of the 19 pa-
tients with a CR or near-CR, the response to bortezo-
mib was their ﬁrst CR. The overall rate of CR+PR was
27%. Twenty-four percent of patients had stable disease;
such patients also experienced a meaningful therapeutic
outcome, since 91% of patients were progressive at the
time of study entry [8].
The response rate to bortezomib was independent of
sex, myeloma type, level of serum b2-microglobulin, and
type and number of previous therapies. Older age (P 65
years) showed a loose association with lower probability
of response; the presence of >50% plasma cells in the
bone marrow at baseline was associated with a statisti-
cally signiﬁcant lower response rate (20% vs. 35% in
those with 6 50% plasma cells; P ¼ 0:03). Presence or
absence of chromosome 13 deletion was not predictive
for response [8].
The median duration of response to bortezomib
among patients with a CR, PR, or MR (n ¼ 67) was 12
months (Fig. 3a). The median time to progression for all
202 patients was 7 months. The median overall survival
for all 202 patients was 16 months (Fig. 3b) [8,11].
Among patients with a CR or PR, 89% had an in-
crease in haemoglobin of at least 1 g/dL, and 72% had
an increase of at least 2 g/dL. As shown in Fig. 4, none
of the responding patients required a transfusion after
cycle 4 [8,12]. Analysis of quality of life (QOL) scores
among 143 patients showed improvements in global
QOL scores and a decrease in the scores for severity of
disease symptoms, pain, and fatigue [8].4%4%4%
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Fig. 4. The SUMMIT trial: red blood cell (RBC) transfusion requiremSeventy-eight patients who had either stable or pro-
gressive disease while being treated with bortezomib
alone subsequently received dexamethasone in combi-
nation with bortezomib. Among 74/78 patients evalu-
able for response, 18% had an MR or PR. Six of these
13 patients had previously been refractory to cortico-
steroid therapy [8].
The side eﬀects associated with bortezomib treatment
are shown in Fig. 5 [8]. The most common adverse
events were gastrointestinal symptoms including nausea
and vomiting, diarrhoea, and constipation; fatigue;
thrombocytopaenia; and sensory neuropathy. The gas- 5  6  7  8
ients Receiving RBC Transfusions 
n Study (Cycle no.)
ents over time [8,12]. Fifty-three patients experienced a CR+PR.
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Fig. 5. The SUMMIT trial: most common adverse experiences [8].
One patient reported grade 4 vomiting (<1%).
J.-L. Harousseau / EJC Supplements Vol 2 No. 6 (2004) 12–17 15trointestinal symptoms were mostly mild to moderate in
severity and were manageable with routine support. The
most common grade 3 adverse events were thrombocy-
topaenia (28%), fatigue (12%), and neuropathy (12%)
[8]. Thrombocytopaenia developed primarily in patients
with a low baseline platelet count, was transient, and
was not associated with serious bleeding complications
[8]. New or worsening peripheral sensory neuropathy
developed in 34% of patients, with a severity of grade
3 in 12%, and no case of grade 4 neuropathy. Im-
provement or complete resolution of neuropathy was
observed in the majority of patients during the follow-
up period. Grade 3 neuropathy developed during
treatment in only one patient who did not have neu-
ropathy at baseline [8].23%19%26%SD
8%12%4%MR
* Overall response rate (ORR). One patient with non-secretory myeloma inevaluable.
†
 Three (11%) and three (12%) patients were not IRC evaluable in 1.0  and 1.3 mg/m2 
dose groups, respectively.
Fig. 6. Response rates to bortezomib alone in the CREST trial [13].3. Bortezomib in patients with relapsed and refractory
myeloma: the CREST trial
A second phase II trial comparing two dose levels of
bortezomib was conducted in patients with somewhat0
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Fig. 7. The CREST trial: most divergent adverse eﬀects. Results show 1.0 an
was similar between doses.earlier stage MM. In the CREST trial, 54 patients who
had relapsed after or were refractory to front-line ther-
apy were randomised to receive bortezomib 1.0 or 1.3
mg/m2 twice weekly for 2 weeks, followed by a 1-week
rest, in 21-day cycles. As in the SUMMIT trial, patients
were permitted to receive up to eight cycles of treatment.
Similarly, the addition of dexamethasone was permitted
for patients with progressive disease after two cycles or
stable disease after four cycles. The primary study end-
point was overall response rate, deﬁned as CR+PR
+MR [13]. Responses were once again assessed by an
independent review committee according to strict Blade
criteria [9].
The response rates in the CREST trial are shown in
Fig. 6 [13]. For patients treated with 1.0 mg/m2, the
overall response rate was 33%, including 11% CR or
near-CR, 19% PR, and 4% MR. For patients treated at
the 1.3 mg/m2 dose, the overall response rate was 50%,
including 4% CR, 35% PR, and 12% MR. Thus, the
response rate appeared to be higher in patients treated at
the higher dose level [13].
Adverse eﬀects observed in the study consisted mainly
of gastrointestinal symptoms, including nausea and
diarrhoea, and peripheral neuropathy. Fig. 7 shows the
comparative incidence of the side eﬀects with the most
divergent incidence rates at the two dose levels in theG4
G3
G1-2
iarrhoea Nausea
m2 1.0 mg/m2 1.3 mg/m21.3 mg/m2
d 1.3 mg/m2 doses by grade [13]. The incidence of other adverse eﬀects
16 J.-L. Harousseau / EJC Supplements Vol 2 No. 6 (2004) 12–17CREST trial [13]. The incidence of diarrhoea and
peripheral neuropathy was appreciably higher at the
1.3 mg/m2 dose, compared with the 1.0 mg/m2 dose [13].
Overall, the CREST trial conﬁrmed the intrinsic ac-
tivity of bortezomib at both dose levels. The higher re-
sponse rate observed with the 1.3 mg/m2 dose suggests a
possible dose–response eﬀect for eﬃcacy. Similarly, the
incidence of several major adverse eﬀects was higher at
the 1.3 mg/m2 dose. Given the relatively small sample
size, a dose–response relationship cannot be conﬁrmed
based on the results of the CREST trial alone. However,
at present it appears appropriate to begin treatment with
bortezomib at a dose of 1.3 mg/m2 with a dose reduction
to 1.0 mg/m2 if indicated [13].4. Conclusions and future directions
The results of the SUMMIT and CREST trials show
that bortezomib is highly active in patients with relapsed
and refractory MM. In the SUMMIT trial, a high re-
sponse rate was seen in a cohort of heavily pre-treated
patients, most of whom had received virtually all avail-
able anti-myeloma therapy. Treatment with bortezomib
was generally well tolerated, with major toxicities in-
cluding manageable gastrointestinal side eﬀects and re-
versible thrombocytopaenia and peripheral neuropathy.
Both thrombocytopaenia and neuropathy occurred
mainly in patients in whom these toxicities had already
been present prior to initiating bortezomib treatment.
Based on the results of the SUMMIT and CREST
trials, it appears reasonable to begin treatment with a
dose of 1.3 mg/m2 and to lower the dose to 1.0 mg/m2 if
necessary for the management of side eﬀects. The re-
sponse rate demonstrated in the CREST study indicates
that 1.0 mg/m2 is an active dose. It is not recommended
to reduce the dose of bortezomib below 0.7 mg/m2.
A large international, randomised phase III trial
comparing bortezomib with high-dose dexamethasone
in patients with relapsed MM (the APEX trial) com-
pleted accrual of more than 600 patients in 2003. The
trial was stopped after a pre-speciﬁed interim analysis
showed a statistically signiﬁcant improvement in time to
disease progression for patients receiving bortezomib.
Additional studies testing bortezomib as front-line
therapy, either as a single agent or in combination
therapy, are ongoing. Encouraging activity using bort-
ezomib in combination with thalidomide [14], melphalan
[15], and liposomal doxorubicin [16] has already been
seen in patients with relapsed and refractory disease.Conﬂict of interest statement
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